Stay informed on developments in cancer and oncology diagnosis, prevention and treatment through these curated webinars. As the race toward a cure for cancer continues, advances in cancer research are constantly revealed as innovation in the field of oncology progresses.
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
RNA sequencing unlocks the mysteries hidden in the transcriptome. Whether your goal is gene expression analysis, gene fusion analysis, SNP analysis or miRNA expression analysis, achieving hig...
In order to expand the treatment options of cancers driven by oncogenic RAS, new cell surface targets need to be identified and characterized. Here, we describe mass spectrometry based phenot...
While circulating cell-free DNA (ccfDNA) and to some extend CTCs from blood are routinely used as analyte in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) ha...
The detection of circulating molecular biomarkers is useful for monitoring pathogenic processes and response to therapeutic intervention1,2. In cancer, genomic and proteomic biomarkers are us...
Understanding the immune repertoire is an important aspect of immuno-oncology research, which can be used to gather insights into the function and overall status of the immune system. We have...
High-throughput screening is widely useful in identifying genes and pathways that drive changes in cell behavior such as cell cycle regulation, metastasis, and drug resistance. Millipor...
Join this year's poster presenters in the Poster Hall during the Poster Networking Hour, Wednesday, September 20th, from 10:00 AM –11:00 AM PDT , to chat live about their posters a...
Immunotherapy: An unprecedented opportunity-Long-lasting/curative treatments-Lower side effects-Wide applicability-Natural mechanism of action-Locally produced T cell therapies&...
The quest to cure cancer through the manipulation the immune system has been at the forefront of science for the past half-decade. The result has been the emergence of a multitude of promisin...
Molecular analyses of cancer biology have tended to segregate between a focus on nucleic acids – DNA, RNA and their modifications – and a focus on proteins and protein function. P...
A hypoxic tumour microenvironment is a feature of solid tumours. Many tumour types contain high fractions of hypoxic tissue. The relationship between high levels of tumour hypoxia and a poor...
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
The oncogenic transcription factor c-MYC (MYC) is deregulated, and often overexpressed, in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease,...
Nanopore sequencing has enormous potential for application to cancer, but specifically offers advantages into two main arenas, epigenetics and structural variation. Methylation is well-known...
Background: Growing evidence supports the critical role of preexisting immune response in triple negative breast cancer (TNBC). However, there are limitations with current evaluation approac...
Genomic data is vast and increasingly sparse. This problem grows as we sequence more and more patients. Herein, Professor Ennis will describe an algorithmic tool that reduces the sparsity of...
The deposition and removal of DNA and histone modifications depends on the availability of specific metabolites, suggesting that cellular metabolic pathways may dynamically regulate chromatin...
The detection of CTCs has been used as useful biomarkers in prognosis and monitoring therapeutic response of patients with metastatic cancer. However, during the course of cancer therapy, CTC...
Recent advances in flow and mass cytometry have greatly expanded the number of immune cell parameters that can be interrogated, resulting in an improved understanding of the immune system het...
The detection of circulating molecular biomarkers is useful for monitoring pathogenic processes and response to therapeutic intervention1,2. In cancer, genomic and proteomic biomarkers are us...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted...
Pancreatic tumors are dynamic pseudo-organs that contain numerous cell types interacting to create unique physiology. A typical pancreatic tumor is made up largely of stromal fibroblasts and...
Exosomes are nano-scale lipid membrane-enclosed extracellular vesicles that form in the cellular endosomal system but are released outside the cell. These virus-sized “fat balls”...
More and more decisions will center on the ability to molecularly characterize a disease. So the molecular diagnostic laboratory will have a pivotal role. What does that look like? Will we be...
Learning Objectives: 1. To provide an overview of relevant hereditary cancer syndromes 2. To encourage providers to obtain a thorough family history 3. To educate providers about available r...
Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype account...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
